Your trusted health, nutrition, and personalized lifestyle medicine resource


COVID-19 and Neurologic Symptoms: What You Need To Know

Presenter: Dale Bredesen, MD

Event Details

Date: June 2, 2020 Start Time: 11:00 AM PT End Time: 12:00 PM PT

Webinar Summary


Dale Bredesen, MD shares his perspective on the neurological impact of COVID-19. One significant concern is the potential for a massive wave of post-COVID neuropsychiatric illness. Dr. Bredeson speaks to his own nutritional approach and highlights the dietary parameters that support resilience, including the benefits of dietary fiber, omega-3 fatty acids, and vitamin D. He also provides insight on the potential benefits of various interventions and the importance of timing based on disease course.

View Now

Presenter Bio


Dale E. Bredesen, MD received his undergraduate degree from Caltech and his medical degree from Duke University. He served as resident and chief resident in neurology at the University of California, San Francisco (UCSF) and as postdoctoral fellow in the laboratory of Nobel Laureate Professor Stanley Prusiner. He was a faculty member at UCLA from 1989 to 1994 and was then recruited by the Burnham Institute to direct the Program on Aging. In 1998, he became the founding president and CEO of the Buck Institute for Research on Aging and adjunct professor at UCSF. In 2013, he returned to the UCLA as director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, which has led to the publication of over 200 research papers. He is the principal investigator for the Alzheimer’s Disease Research Center at UCLA. He established the Alzheimer’s Drug Development Network (ADDN) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. His group has developed a new approach to the treatment of Alzheimer’s disease, the MEND protocol, and this approach has led to the first description of a reversal of symptoms in patients with mild cognitive impairment (MCI) and early Alzheimer’s disease.

Metagenics Institute is a trusted, peer-to-peer, evidence-based educational resource for nutrition and personalized medicine.
At Metagenics Institute, we translate credible research with scientific integrity into innovative and actionable clinical
decision-making. Metagenics Institute supports a diverse practitioner base to optimize patient outcomes by shifting existing paradigms in healthcare. Our mission is to transform healthcare by inspiring and educating practitioners, and their patients, about personalized lifestyle medicine.

Sponsored by
© 2024 Metagenics Institute. All Rights Reserved